Conformational active peptides for antiviral therapy.
Conformational active peptides are making waves in antiviral research. Instead of blocking viruses with brute force, these peptides work smarter: they force viral proteins to twist, warp, and lose function. Rubel and Egorov’s latest review shines a light on this strategy, mapping out how direct-acting peptides can push viral proteins into dysfunctional shapes—sometimes even triggering prion-like changes that cripple viruses from the inside out.
Bioorg Chem
by Rubel AA, Egorov VV
“Conformational active peptides for antiviral therapy. Rubel AA(1), Egorov VV(1). Author information: (1)Laboratory of Amyloid Biology, St. Petersburg State University, St. Petersburg 199034, Russia. This review describes a class of etiotropic (direct-acting) antiviral agents that act by altering the conformation of microbial proteins and thereby disrupting their functions. Examples of peptides capable of inducing a prion-like change in viral protein conformation are considered. The potential applications of such compounds and potential challenges associated with their use are discussed. Copyright © 2026 Elsevier Inc. All rights reserved. Conflict of interest statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.”
This approach isn’t just theoretical. Researchers are already testing peptides that can hijack viral machinery by targeting the shape of key proteins. If a virus can’t hold its shape, it can’t infect. Simple as that.
Key takeaway: These conformational active peptides don’t just block infection—they attack the blueprint of the virus itself.
Why does this matter for peptide researchers?
Direct manipulation of viral protein structure opens up new targets for peptide design.
Prion-like induction could give peptides longer-lasting effects compared to traditional antivirals.
The strategy is broad: it might hit multiple virus types, not just one.
There’s still work to be done on delivery, stability, and making sure these peptides only hit viral proteins, not human ones.
The review also highlights some hurdles—like getting peptides into cells efficiently and making sure they don’t misfire. But the door is wide open for new peptide research and smarter design.
For anyone sourcing or developing new research compounds, this field is one to watch. Check out the vendor directory to see what’s available for your next project.
Bottom line: manipulating protein conformation with peptides could be the next frontier in antiviral research. The potential for innovation here is massive.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.